开发肿瘤药物的现代疾病建模方法

Cardiometry Pub Date : 2023-11-01 DOI:10.18137/cardiometry.2023.29.conf.12

V. Khokhlova, O. Bezborodova, G. V. Trunova, E. A. Plotnikova, N. Morozova, A. Plyutinskaya, M. S. Vorontsova, Yu. B. Venediktova, E. Nemtsova, A. Pankratov, P. V. Shegai

{"title":"开发肿瘤药物的现代疾病建模方法","authors":"V. Khokhlova, O. Bezborodova, G. V. Trunova, E. A. Plotnikova, N. Morozova, A. Plyutinskaya, M. S. Vorontsova, Yu. B. Venediktova, E. Nemtsova, A. Pankratov, P. V. Shegai","doi":"10.18137/cardiometry.2023.29.conf.12","DOIUrl":null,"url":null,"abstract":"Oncological diseases are characterized by the complexity of pathogenesis and demonstrate a number of specific signs, such as uncontrolled proliferation, stimulation of angiogenesis, activation of invasion and metastasis. Molecular genetic testing to examine genetic abnormalities in tumor cells has been increasingly using in oncology. With an accumulation of the data on the repertoire of mutations or other events in the patient’s tumors, new goals for the development of more targeted and specific antitumor therapies appear. For example, membrane proteins EGFR, HER-2, PSMA and C-met are identified as such targets. Despite the large volume of research conducted, no more than 11% of the total drug candidates are approved by regulatory authorities for clinical use. This is often due to their lack of effectiveness and the incomparability of the results obtained in preclinical trials in animal models with actual results in patients. Therefore, the development of experimental approaches for modeling tumor processes in laboratory animals is an urgent problem.","PeriodicalId":41726,"journal":{"name":"Cardiometry","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A MODERN APPROACH TO DISEASE MODELING FOR THE DEVELOPMENT OF ONCOLOGY DRUGS\",\"authors\":\"V. Khokhlova, O. Bezborodova, G. V. Trunova, E. A. Plotnikova, N. Morozova, A. Plyutinskaya, M. S. Vorontsova, Yu. B. Venediktova, E. Nemtsova, A. Pankratov, P. V. Shegai\",\"doi\":\"10.18137/cardiometry.2023.29.conf.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Oncological diseases are characterized by the complexity of pathogenesis and demonstrate a number of specific signs, such as uncontrolled proliferation, stimulation of angiogenesis, activation of invasion and metastasis. Molecular genetic testing to examine genetic abnormalities in tumor cells has been increasingly using in oncology. With an accumulation of the data on the repertoire of mutations or other events in the patient’s tumors, new goals for the development of more targeted and specific antitumor therapies appear. For example, membrane proteins EGFR, HER-2, PSMA and C-met are identified as such targets. Despite the large volume of research conducted, no more than 11% of the total drug candidates are approved by regulatory authorities for clinical use. This is often due to their lack of effectiveness and the incomparability of the results obtained in preclinical trials in animal models with actual results in patients. Therefore, the development of experimental approaches for modeling tumor processes in laboratory animals is an urgent problem.\",\"PeriodicalId\":41726,\"journal\":{\"name\":\"Cardiometry\",\"volume\":\"30 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiometry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18137/cardiometry.2023.29.conf.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiometry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18137/cardiometry.2023.29.conf.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

肿瘤疾病的特点是发病机制复杂，并表现出许多特殊征兆，如增殖失控、刺激血管生成、激活侵袭和转移。在肿瘤学中，越来越多地使用分子基因检测来检查肿瘤细胞的基因异常。随着患者肿瘤中突变或其他事件的数据不断积累，开发更具针对性和特异性的抗肿瘤疗法的新目标也随之出现。例如，膜蛋白表皮生长因子受体（EGFR）、HER-2、PSMA 和 C-met 被确定为此类靶点。尽管开展了大量研究，但只有不超过 11% 的候选药物被监管机构批准用于临床。这通常是由于这些药物缺乏有效性，以及在动物模型中进行的临床前试验结果与患者的实际结果无法比较。因此，开发在实验动物中模拟肿瘤过程的实验方法是一个亟待解决的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A MODERN APPROACH TO DISEASE MODELING FOR THE DEVELOPMENT OF ONCOLOGY DRUGS

Oncological diseases are characterized by the complexity of pathogenesis and demonstrate a number of specific signs, such as uncontrolled proliferation, stimulation of angiogenesis, activation of invasion and metastasis. Molecular genetic testing to examine genetic abnormalities in tumor cells has been increasingly using in oncology. With an accumulation of the data on the repertoire of mutations or other events in the patient’s tumors, new goals for the development of more targeted and specific antitumor therapies appear. For example, membrane proteins EGFR, HER-2, PSMA and C-met are identified as such targets. Despite the large volume of research conducted, no more than 11% of the total drug candidates are approved by regulatory authorities for clinical use. This is often due to their lack of effectiveness and the incomparability of the results obtained in preclinical trials in animal models with actual results in patients. Therefore, the development of experimental approaches for modeling tumor processes in laboratory animals is an urgent problem.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cardiometry MEDICAL LABORATORY TECHNOLOGY-

自引率

0.00%

发文量

审稿时长

6 weeks

期刊介绍： Cardiometry is an open access biannual electronic journal founded in 2012. It refers to medicine, particularly to cardiology, as well as oncocardiology and allied science of biophysics and medical equipment engineering. We publish mainly high quality original articles, reports, case reports, reviews and lectures in the field of the theory of cardiovascular system functioning, principles of cardiometry, its diagnostic methods, cardiovascular system therapy from the aspect of cardiometry, system and particular approaches to maintaining health, engineering peculiarities in cardiometry developing. The interdisciplinary areas of the journal are: hemodynamics, biophysics, biochemistry, metrology. The target audience of our Journal covers healthcare providers including cardiologists and general practitioners, bioengineers, biophysics, medical equipment, especially cardiology diagnostics device, developers, educators, nurses, healthcare decision-makers, people with cardiovascular diseases, cardiology and engineering universities and schools, state and private clinics. Cardiometry is aimed to provide a wide forum for exchange of information and public discussion on above scientific issues for the mentioned experts.